Summary

The global influenza diagnostics market is set to experience robust growth over the forecast period 2025 to 2032. With the increasing burden of seasonal influenza and the global push for early detection of viral infections, the market is projected to rise from USD 2 Bn in 2025 to USD 3.3 Bn by 2032, progressing at a CAGR of 7.42%. The growing need for rapid, accurate diagnostic methods and the shift toward decentralized testing are among the key growth stimulants.

Market Insights

The evolution of diagnostic technology has led to a significant transformation in influenza detection, moving from traditional laboratory testing to highly sensitive and faster point-of-care molecular diagnostics. Innovations such as RT-PCR, nucleic acid amplification tests (NAATs), and rapid influenza diagnostic tests (RIDTs) have increased the efficiency and accessibility of flu diagnosis.

Commercial rapid flu tests have become the dominant method for influenza detection due to their speed and ease of use. However, molecular diagnostics such as RT-PCR remain the gold standard, especially in clinical settings requiring higher accuracy.

Market Drivers

One of the most compelling drivers of the influenza diagnostics market is the increasing prevalence of seasonal flu globally. Rising flu cases have led to heightened awareness regarding early diagnosis and timely treatment, further pushing the demand for diagnostic kits and platforms.

Additionally, continuous advancements in molecular technologies have enabled precise detection of influenza viruses, including Type A and Type B strains. RT-PCR and other molecular assays offer improved sensitivity and specificity, which are essential in both clinical and research settings.

Investments in research and development have also played a crucial role in accelerating innovation. Government and private sector funding support has expanded influenza diagnostic capabilities across countries. Programs such as the Vaccine and Therapy Evaluation Units (VTEUs) and the Collaboration Influenza Vaccine Innovations Centers (CIVICs) have been instrumental in facilitating research and improving diagnostic readiness.

Business Opportunity

The ongoing shift from centralized laboratories to decentralized, point-of-care (POC) testing environments offers a major business opportunity for manufacturers and diagnostic service providers. CLIA-waived molecular tests, which are easy to use and deliver results within minutes, are increasingly being adopted in outpatient clinics, pharmacies, and even at home.

The global shortage of skilled personnel to operate complex diagnostic systems remains a challenge, yet it also opens the door for automated and user-friendly diagnostic solutions. Market players investing in low-cost, easy-to-use molecular kits tailored for emerging economies are expected to gain significant traction.

Region Analysis

North America dominates the global influenza diagnostics market, with the U.S. leading due to the country’s advanced healthcare infrastructure, high influenza prevalence, and active involvement of major companies like Abbott and Quidel Corporation in product development.

In Europe, Germany represents a lucrative market owing to the presence of strong diagnostic manufacturing capabilities, favorable government support, and rising cases of seasonal flu.

Japan holds a significant share in East Asia, fueled by an aging population, growing incidence of infectious diseases, and the country’s proactive approach in adopting cutting-edge diagnostic technologies.

Key Players

The competitive Analysis of the influenza diagnostics market is characterized by strategic mergers, acquisitions, and product innovations. Leading players are focused on expanding their portfolio to cater to the growing diagnostic demand.

• Thermo Fisher Scientific Inc. offers accessible and collaborative RT-PCR solutions with cloud-based data sharing.

• Quidel Corporation gained FDA approval for its Sofia 2 Flu + SARS Antigen FIA, combining detection for both flu and COVID-19.

• Roche’s acquisition of GenMark Diagnostics has strengthened its molecular diagnostics capabilities.

Other notable companies include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux Inc., Cepheid (Danaher Corporation), GenMark Diagnostics, Inc., Luminex Corporation, Meridian Bioscience, Inc., and Hologic.

Market Segmentation

Test Type

• Molecular Diagnostic Test

o RT-PCR

o LAMP

o NASABA

• Traditional Diagnostic Test

o Rapid Influenza Detection Test

o Serological Assays

o Direct Fluorescent Antibody

o Viral Culture

o H1N1 Influenza A Virus Identification Kits

o Immunoassay Kits

o Immunofluorescence Antibody Assay

Type of Flu

• Type A Flu

• Type B Flu

• Type C Flu

End User

• Hospitals

• Diagnostic Laboratories

• Research & Academic Institutes

• Contract Research Organizations (CROs)

Region

• North America

• Latin America

• Europe

• South Asia

• East Asia

• Oceania

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Influenza Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Influenza Diagnostics Market Outlook, 2019-2032
3.1. Global Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Molecular Diagnostic Test
3.1.1.1.1. RT-PCR
3.1.1.1.2. LAMP
3.1.1.1.3. NASABA
3.1.1.2. Traditional Diagnostic Test
3.1.1.2.1. Rapid Influenza Detection Test
3.1.1.2.2. Serological Assays
3.1.1.2.3. Direct Fluorescent Antibody
3.1.1.2.4. Viral Culture
3.1.1.2.5. H1N1 Influenza A Virus Identification Kits
3.1.1.2.6. Immunoassay Kits
3.1.1.2.7. Immunofluorescence Antibody Assay
3.2. Global Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Type A Flu
3.2.1.2. Type B Flu
3.2.1.3. Type C Flu
3.3. Global Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Diagnostic Laboratories
3.3.1.3. Research & Academic Institute
3.3.1.4. Contract Research Organization (CRO’s)
3.4. Global Influenza Diagnostics Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Influenza Diagnostics Market Outlook, 2019-2032
4.1. North America Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Molecular Diagnostic Test
4.1.1.1.1. RT-PCR
4.1.1.1.2. LAMP
4.1.1.1.3. NASABA
4.1.1.2. Traditional Diagnostic Test
4.1.1.2.1. Rapid Influenza Detection Test
4.1.1.2.2. Serological Assays
4.1.1.2.3. Direct Fluorescent Antibody
4.1.1.2.4. Viral Culture
4.1.1.2.5. H1N1 Influenza A Virus Identification Kits
4.1.1.2.6. Immunoassay Kits
4.1.1.2.7. Immunofluorescence Antibody Assay
4.2. North America Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Type A Flu
4.2.1.2. Type B Flu
4.2.1.3. Type C Flu
4.3. North America Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospitals
4.3.1.2. Diagnostic Laboratories
4.3.1.3. Research & Academic Institute
4.3.1.4. Contract Research Organization (CRO’s)
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Influenza Diagnostics Market Outlook, 2019-2032
5.1. Europe Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Molecular Diagnostic Test
5.1.1.1.1. RT-PCR
5.1.1.1.2. LAMP
5.1.1.1.3. NASABA
5.1.1.2. Traditional Diagnostic Test
5.1.1.2.1. Rapid Influenza Detection Test
5.1.1.2.2. Serological Assays
5.1.1.2.3. Direct Fluorescent Antibody
5.1.1.2.4. Viral Culture
5.1.1.2.5. H1N1 Influenza A Virus Identification Kits
5.1.1.2.6. Immunoassay Kits
5.1.1.2.7. Immunofluorescence Antibody Assay
5.2. Europe Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Type A Flu
5.2.1.2. Type B Flu
5.2.1.3. Type C Flu
5.3. Europe Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Diagnostic Laboratories
5.3.1.3. Research & Academic Institute
5.3.1.4. Contract Research Organization (CRO’s)
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.1.7. France Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.8. France Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.9. France Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Influenza Diagnostics Market Outlook, 2019-2032
6.1. Asia Pacific Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Molecular Diagnostic Test
6.1.1.1.1. RT-PCR
6.1.1.1.2. LAMP
6.1.1.1.3. NASABA
6.1.1.2. Traditional Diagnostic Test
6.1.1.2.1. Rapid Influenza Detection Test
6.1.1.2.2. Serological Assays
6.1.1.2.3. Direct Fluorescent Antibody
6.1.1.2.4. Viral Culture
6.1.1.2.5. H1N1 Influenza A Virus Identification Kits
6.1.1.2.6. Immunoassay Kits
6.1.1.2.7. Immunofluorescence Antibody Assay
6.2. Asia Pacific Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Type A Flu
6.2.1.2. Type B Flu
6.2.1.3. Type C Flu
6.3. Asia Pacific Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Diagnostic Laboratories
6.3.1.3. Research & Academic Institute
6.3.1.4. Contract Research Organization (CRO’s)
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
6.4.1.2. China Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
6.4.1.3. China Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
6.4.1.10. India Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
6.4.1.11. India Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
6.4.1.12. India Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Influenza Diagnostics Market Outlook, 2019-2032
7.1. Latin America Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Molecular Diagnostic Test
7.1.1.1.1. RT-PCR
7.1.1.1.2. LAMP
7.1.1.1.3. NASABA
7.1.1.2. Traditional Diagnostic Test
7.1.1.2.1. Rapid Influenza Detection Test
7.1.1.2.2. Serological Assays
7.1.1.2.3. Direct Fluorescent Antibody
7.1.1.2.4. Viral Culture
7.1.1.2.5. H1N1 Influenza A Virus Identification Kits
7.1.1.2.6. Immunoassay Kits
7.1.1.2.7. Immunofluorescence Antibody Assay
7.2. Latin America Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
7.2.1.1. Type A Flu
7.2.1.2. Type B Flu
7.2.1.3. Type C Flu
7.3. Latin America Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Diagnostic Laboratories
7.3.1.3. Research & Academic Institute
7.3.1.4. Contract Research Organization (CRO’s)
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Influenza Diagnostics Market Outlook, 2019-2032
8.1. Middle East & Africa Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Molecular Diagnostic Test
8.1.1.1.1. RT-PCR
8.1.1.1.2. LAMP
8.1.1.1.3. NASABA
8.1.1.2. Traditional Diagnostic Test
8.1.1.2.1. Rapid Influenza Detection Test
8.1.1.2.2. Serological Assays
8.1.1.2.3. Direct Fluorescent Antibody
8.1.1.2.4. Viral Culture
8.1.1.2.5. H1N1 Influenza A Virus Identification Kits
8.1.1.2.6. Immunoassay Kits
8.1.1.2.7. Immunofluorescence Antibody Assay
8.2. Middle East & Africa Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Type A Flu
8.2.1.2. Type B Flu
8.2.1.3. Type C Flu
8.3. Middle East & Africa Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Diagnostic Laboratories
8.3.1.3. Research & Academic Institute
8.3.1.4. Contract Research Organization (CRO’s)
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Influenza Diagnostics Market by Test, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Influenza Diagnostics Market by End User, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Segment 3 vs by Type of Flu Heat map
9.2. Manufacturer vs by Type of Flu Heatmap
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Abbott Laboratories
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Endress+Hauser (Analytik Jena AG)
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Becton, Dickinson and Company
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Biocartis
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. bioMérieux Inc
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Danaher Corporation (Cepheid)
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. F. Hoffmann-La Roche Ltd
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. GenMark Diagnostics, Inc.
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Luminex Corporation
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Quidel Corporation
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Genesis Biosystems, Inc.
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Thermo Fisher Scientific Inc.
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Hologic
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations